Department of Pathology & Laboratory Medicine
Medical University of South Carolina
Charleston, SC 29425

Mission:

The Laboratory for Stem Cell Injury is directed by Dr. Daohong Zhou, a professor in the Department of Pathology and Laboratory Medicine at Medical University of South Carolina. The research interests of the laboratory include:

• To elucidate the cellular and molecular mechanisms by which ionizing radiation (IR) and chemotherapy cause normal tissue damage and develop new mechanism-based interventions to ameliorate IR and chemotherapy-induced normal tissue injury.
• To study the long-term effects of genotoxic stress/DNA damage induced by IR and chemotherapy on hematopoietic stem cell (HSC) self-renewal, genomic stability, and plasticity and the role of HSC injury in IR- and chemotherapy-induced long-term bone marrow suppression, leukemogenesis, and premature ageing in an animal model.
• To delineate the underlying mechanisms of leukemia and tumor resistance to IR and chemotherapy.

Director:

Daohong Zhou, MD

Background of Director:

MD, 1982, Yunyang Medical College, China
MS, 1986, Henan Medical University, China
Postdoctoral Fellowship, 1990-92, Johns Hopkins University School of Medicine
1986-90, Lecturer, Dept. of Microbiology/Immunology; Henan Medical University
1992-95, Research Associate, Dept. of Pathology; University of Pittsburgh
1995-96, Senior Res. Associate, Dept. of Internal Medicine; University of Kentucky 
1996-2000, Assistant Professor, Dept. of Internal Medicine; University of Kentucky
2000-07, Associate Professor, Dept. of Pathology & Lab. Medicine; Medical University of SC (MUSC)
2000- present, Full Member, College of Graduate Studies; MUSC  
2000- present, Full Member, Hollings Cancer Center; MUSC  
2001-07, Director, Shared Irradiator Facility of Hollings Cancer Center; MUSC
2001-07, Director, Flow Cytometry & Cell Sorting Core Facility of Hollings Cancer Center; MUSC
2007- present, Professor, Dept. of Pathology & Lab. Medicine.; MUSC

Other Experience and Current Professional Memberships:

• Member of the Radiation Research Society, American Association of Immunologists, International Society of Experimental Hematology, American Society of Hematology, and the International Society of Stem Cell Research.
• Member of the NIH Special Emphasis Panel: ZRG1 ONC-H (02) (2007); ZRG1 ONC-R (11S) (2006); ZAG1 HEME-D (10) (2005-2006); ZRG1 Heme-D (02) (2005); Member of NIH Site Visit Committee, Georgetown University, Washington DC (2002)
• Ad hoc grant reviewer: the RTB Study Section of NIH (2007); the U.S. Army Medical Research and Materiel Command (USAMRMC) (2006); the Chinese Science Foundation (2006); the Health Research Board of Ireland (2005); and the United States Civilian Research and Development Foundation (2000-present)
• Ad hoc reviewer: Am J Pathol, Anat Rec, Anti-Cancer Drugs, Biochem Pharmacol, Cancer Res, Cancer Lett, Cell and Clin Med & Res, Cytokine, Eur J Immunol, FEBS Lett, Haematologica, Int J Biomed Sci, Int J Radiat Biol, J Neurochem, J Neuroimmunol, J Radiat Res, Leukemia, Leukemia Res, Mol Cancer Res, Mol Life Sci, Oncogene

Current Projects:

• Cancer therapy-induced long-term bone marrow toxicity
• Radiation-induced lymphoid and hematopoietic toxicity
• Role of p38 MAPK in HSC self-renewal and radiation-induced bone marrow injury

Website:
http://www.musc.edu/pathology/stemcellinjury/